Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Stocktwits on MSN3d
Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day In 17 Years On Weak Guidance
Merck & Co. Inc. shares plunged more than 10% on Tuesday as a weak 2025 outlook overshadowed its upbeat fourth-quarter ...
Morningstar4d
Merck's struggles with HPV vaccine send stock to worst selloff in almost 17 years
Merck issued guidance for 2025 that lags consensus ... Those were partially offset by lower sales of diabetic medicines Januvia and Janumet, and lower combined sales of the human papillomavirus ...
Morningstar4d
Merck's soft guidance overshadows quarterly beat to send stock down 8%
Januvia and Janumet sales fell 38% to $487 million ... which proved to be as effective when given intravenously. Merck said it would discuss the results with regulators worldwide.
Merck Stock Down 8% On Weak Outlook, Q4 Results Miss Estimates
Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...
NBC Connecticut4d
Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Merck's Type 2 diabetes treatment, Januvia, also saw sales fall to $487 million during the quarter, down 38% from the same period a year ago. The company said the decline was primarily due to ...